9 - ATTD 2025 Highlights and New CGMs (Good, Bad and Ugly!)

Suggest guests or get in contactIn this episode of the Glucose Never Lies podcast, John Pemberton shares insights from the ATTD 2025 conference, discussing advancements in diabetes management technologies, including automated insulin delivery systems and continuous glucose monitoring. He emphasizes the importance of early intervention with AID systems, the role of GLP-1 receptor agonists, and the impact of exercise and nutrition on diabetes control. The conversation also highlights the need for equitable access to diabetes technology and the improvements in quality of life that these innovations can bring.TakeawaysAutomated insulin delivery systems can improve glycemic control and quality of life.Starting AID systems early can lead to better long-term outcomes.GLP-1 receptor agonists show promise for type 2 diabetes management.Exercise plays a significant role in managing diabetes effectively.Nutrition strategies are essential for optimizing insulin delivery systems.Equity in access to diabetes technology is a pressing issue.Continuous glucose monitoring devices are rapidly evolving.The future of diabetes management looks promising with new technologies.Chapters00:00Introduction to the Podcast and Personal Journey02:14Insights from ATTD 2025 Conference03:41Advancements in Automated Insulin Delivery Systems08:22Exploring GLP-1 Receptor Agonists and Insulin Resistance10:42The Role of Exercise in Diabetes Management14:07Nutrition and Automated Insulin Delivery Systems16:03Quality of Life Improvements with AID Systems17:55Equity in Access to Diabetes Technology19:18Continuous Glucose Monitoring Innovations24:05Future Directions in Diabetes Management  Show Notes & ResourcesFull Show Notes - Episode 9: ATTD 2025 🎧 Download the Glucose Rap📘 Insulin Resistance Guide📊 CGM Accuracy Series🎙️ Episode 8: Activity for Post-Meal Glucose Control📎 Episode 6: Ten Tips to Optimise Time in Range with AID. Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.DisclaimerThis podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.The Glucose Never Lies® is independent by designWe do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:Buying the GNL a Coffee:https://www.buymeacoffee.com/jspfree2EnquiriesCollaboration: John Pemberton — [email protected]: Anjanee Kohli — [email protected] The Glucose Never Lies®Website: https://theglucoseneverlies.com/Instagram: https://www.instagram.com/theglucoseneverliesLinkedIn: https://www.linkedin.com/company/theglucoseneverliesLinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/X: https://twitter.com/GlucoseNLiesDisclaimer This content is for informational purposes only and does not constitute medical advice.© The Glucose Never Lies Ltd. All rights reserved.